Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus.
Saved in:
| Title: | Safety, tolerability, pharmacokinetics and pharmacodynamic effects of desmoglein 3 peptide-coupled tolerizing nanoparticles in pemphigus. |
|---|---|
| Authors: | Didona D; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany., Hudemann C; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany., Garn H; Translational Inflammation Research Division and Core Facility for Single Cell Multiomics, Biochemical-Pharmacological Center, Philipps-Universität Marburg, Marburg, Germany., Krzikalla D; Topas Therapeutics (Topas), Hamburg, Germany., Wang SH; Topas Therapeutics (Topas), Hamburg, Germany., Hinterseher J; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany., Volkmann K; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany., Polakova A; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany., Zakrzewicz A; Institute of Biochemistry, Medical Faculty, University of Giessen, Germany., Feldhoff S; Institute of Biochemistry, Medical Faculty, University of Giessen, Germany., Tikkanen R; Institute of Biochemistry, Medical Faculty, University of Giessen, Germany., Digigow R; Topas Therapeutics (Topas), Hamburg, Germany., Pfützner W; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany., Santos A; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany., Zimmer CL; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany., Hahmann M; Coordination Center for Clinical Studies (KKS), Philipps-Universität Marburg, Marburg, Germany., Harnisch S; Coordination Center for Clinical Studies (KKS), Philipps-Universität Marburg, Marburg, Germany., Rösch S; Topas Therapeutics (Topas), Hamburg, Germany., Huguenin S; Topas Therapeutics (Topas), Hamburg, Germany., Eming R; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany.; Department of Dermatology, Venerology and Allergology, Central Military Hospital, Koblenz, Germany., Hahn M; Department of Dermatology, Eberhard Karls University, Tübingen, Germany., Schauer F; Department of Dermatology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Antiga E; Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy., Senatore S; Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy., Maglie R; Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Italy., Täubel J; City St George's, University of London, UK., Ghoreschi K; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Meier K; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Solimani F; Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany., Sticherling M; Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Germany., Sollfrank L; Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Deutsches Zentrum Immuntherapie (DZI), Uniklinikum Erlangen, Germany., Günther C; Department of Dermatology, University of Dresden, Germany., Steinbrink K; Department of Dermatology, University Hospital of Münster, Münster, Germany., Magnolo N; Department of Dermatology, University Hospital of Münster, Münster, Germany., van Schaick E; Topas Therapeutics (Topas), Hamburg, Germany., Asnaghi V; Topas Therapeutics (Topas), Hamburg, Germany., Zollmann FS; Topas Therapeutics (Topas), Hamburg, Germany., Pohlner J; Topas Therapeutics (Topas), Hamburg, Germany., Hummel J; Topas Therapeutics (Topas), Hamburg, Germany., Sandbrink R; Topas Therapeutics (Topas), Hamburg, Germany., de Min C; Topas Therapeutics (Topas), Hamburg, Germany., Fleischer S; Topas Therapeutics (Topas), Hamburg, Germany., Möbs C; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany., Hertl M; Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany. |
| Source: | The British journal of dermatology [Br J Dermatol] 2026 Jan 06; Vol. 194 (1), pp. 86-98. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
